New vaccine aims to block more Cancer-Causing HPV strains
NCT ID NCT04537156
First seen Nov 21, 2025 · Last updated Apr 20, 2026 · Updated 15 times
Summary
This large Phase 3 trial is testing a new 9-valent HPV vaccine designed to protect against nine types of human papillomavirus. It aims to prevent cervical cancer, precancerous lesions, and genital warts in healthy women aged 18 to 45. The study compares the new vaccine's effectiveness and safety against an existing 2-valent HPV vaccine.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Jiangsu Provincial Centre for Disease Control and Prevention
Nanjing, Jiangsu, 210009, China
-
Sichuan Provincial Centre for Disease Control and Prevention
Chengdu, Sichuan, 610041, China
Conditions
Explore the condition pages connected to this study.